Sigma-Aldrich, Oxford BioMedica Settle Litigation with Open Biosystems | GenomeWeb
NEW YORK (GenomeWeb News) – Sigma-Aldrich and Oxford BioMedica said today that they have settled their two-year-old litigation with Open Biosystems over patents covering lentiviral vector technology.
Sigma-Aldrich and Oxford agreed to dismiss their suit against Open Bio, and Open Bio agreed to dismiss its counterclaims. As part of the settlement, Open Bio will acquire certain licensing rights to patents covering the use of Oxford’s LentiVector technology in research activities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.